Outcomes were examined in 2 randomized, double-blind, placebo-controlled, parallel-group clinical trials: PIONEER I (ClinicalTrials.gov identifier: NCT01468207) and PIONEER II (ClinicalTrials.gov identifier: NCT01468233).
Pfizer has announced top-line results from its Phase 3B/4 study comparing treatment with Xeljanz to adalimumab in patients with moderate to severe rheumatoid arthritis.
"Improved pain management should be explored in patients who report high disease activity."
While the MUSICA trial did not establish noninferiority for a lower dosage of MTX when combined with adalimumab, it may be an appropriate option for patients who require a reduction due to MTX toxicity.
Clinical Pain Advisor Articles
- Replacing Sleep, Sedentary Behavior With Physical Activity Beneficial in Knee Osteoarthritis
- FDA Outlines Plan for New Analgesic Guidance to Combat Opioid Crisis
- The Role of Psychological Factors in Phantom Limb Pain Reviewed
- Rates of Concurrent Opioid, Sedative-Hypnotic Prescription Fills in Veterans
- Ozone vs Corticosteroids May Provide Longer-Lasting Effects for Plantar Fasciitis
- Ketamine: Mechanisms of Action, Uses in Pain Medicine, and Side Effects
- Medicinal Cannabis May Not Have Opioid-Sparing Effects in Chronic Noncancer Pain
- Cannabis May Be Effective for Migraine Treatment
- Integrating Psychological Interventions Into Chronic Pain Management
- Chronic Neck Pain: Generators, Clinical Examination, MRI Findings, and Differential Diagnosis
- Pregabalin May Not Improve Analgesia During Medical Abortion
- Investigational Treatment Shows Promise in Chronic Low Back Pain
- Rheumatologist-Assessed vs Criteria for Inflammatory Back Pain in Psoriatic Arthritis
- Incorporating Guidelines Into Clinical Practice: An Interview With Gary L. LeRoy, MD
- Pain Severity May Partly Mediate the Association Between Depression and Physical Performance in Knee OA